Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
25.47
USD
|
+0.87%
|
|
+30.82%
|
+33.07%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,026
|
1,487
|
2,204
|
1,176
|
1,697
|
2,305
|
-
|
-
|
Enterprise Value (EV)
1 |
2,122
|
1,595
|
1,864
|
1,061
|
1,595
|
2,211
|
2,189
|
2,142
|
P/E ratio
|
454
x
|
-6.42
x
|
-78.9
x
|
-10.4
x
|
-6.02
x
|
-28.3
x
|
-39
x
|
-91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.38
x
|
2.67
x
|
3.19
x
|
1.73
x
|
2.25
x
|
2.77
x
|
2.57
x
|
2.4
x
|
EV / Revenue
|
2.49
x
|
2.86
x
|
2.7
x
|
1.56
x
|
2.12
x
|
2.66
x
|
2.44
x
|
2.23
x
|
EV / EBITDA
|
9.73
x
|
-
|
25.9
x
|
-50.5
x
|
-253
x
|
91.2
x
|
37.8
x
|
26.2
x
|
EV / FCF
|
28.3
x
|
-24.7
x
|
11.5
x
|
-7
x
|
-9.16
x
|
553
x
|
137
x
|
54.9
x
|
FCF Yield
|
3.54%
|
-4.05%
|
8.7%
|
-14.3%
|
-10.9%
|
0.18%
|
0.73%
|
1.82%
|
Price to Book
|
1.84
x
|
1.69
x
|
2.28
x
|
1.33
x
|
2.2
x
|
3.02
x
|
3.01
x
|
2.93
x
|
Nbr of stocks (in thousands)
|
74,389
|
75,210
|
79,855
|
81,034
|
88,669
|
90,508
|
-
|
-
|
Reference price
2 |
27.23
|
19.78
|
27.60
|
14.51
|
19.14
|
25.47
|
25.47
|
25.47
|
Announcement Date
|
8/13/19
|
2/23/21
|
2/24/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
851.1
|
557
|
690.6
|
678.4
|
753.2
|
831.5
|
896.3
|
960.7
|
EBITDA
1 |
218.2
|
-
|
71.9
|
-21
|
-6.3
|
24.25
|
57.87
|
81.82
|
EBIT
1 |
145.2
|
-77.9
|
9.1
|
-32.8
|
-25.5
|
4.769
|
24.71
|
44.66
|
Operating Margin
|
17.06%
|
-13.99%
|
1.32%
|
-4.83%
|
-3.39%
|
0.57%
|
2.76%
|
4.65%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-57.1
|
-140.6
|
-262.2
|
-106.5
|
-72.47
|
-33.36
|
Net income
1 |
4.6
|
-
|
-27.2
|
-112
|
-263.3
|
-89.74
|
-59.12
|
-25.19
|
Net margin
|
0.54%
|
-
|
-3.94%
|
-16.51%
|
-34.96%
|
-10.79%
|
-6.6%
|
-2.62%
|
EPS
2 |
0.0600
|
-3.080
|
-0.3500
|
-1.390
|
-3.180
|
-0.9000
|
-0.6533
|
-0.2800
|
Free Cash Flow
1 |
75.1
|
-64.6
|
162.2
|
-151.6
|
-174.1
|
4
|
16
|
39
|
FCF margin
|
8.82%
|
-11.6%
|
23.49%
|
-22.35%
|
-23.11%
|
0.48%
|
1.79%
|
4.06%
|
FCF Conversion (EBITDA)
|
34.42%
|
-
|
225.59%
|
-
|
-
|
16.49%
|
27.65%
|
47.67%
|
FCF Conversion (Net income)
|
1,632.61%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/13/19
|
2/23/21
|
2/24/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
160.8
|
164.9
|
179.3
|
156.4
|
177.8
|
181.2
|
183.5
|
191.9
|
196.6
|
202.2
|
205.4
|
208.3
|
217.7
|
214.6
|
221.8
|
EBITDA
1 |
13.4
|
10.2
|
7.3
|
-17.6
|
-10.7
|
-20.5
|
-4.2
|
1.2
|
10.1
|
4.4
|
5
|
6
|
7
|
6
|
-
|
EBIT
1 |
0.1
|
-2.8
|
4.5
|
-20.6
|
-13.9
|
-21.9
|
-6.8
|
-2.2
|
5.7
|
-0.6
|
-0.6337
|
0.8552
|
5.276
|
1.886
|
4.5
|
Operating Margin
|
0.06%
|
-1.7%
|
2.51%
|
-13.17%
|
-7.82%
|
-12.09%
|
-3.71%
|
-1.15%
|
2.9%
|
-0.3%
|
-0.31%
|
0.41%
|
2.42%
|
0.88%
|
2.03%
|
Earnings before Tax (EBT)
1 |
-43.5
|
-26.4
|
-17.9
|
-44.2
|
-52.1
|
-52.6
|
-116.1
|
-61.2
|
-32.3
|
-25.9
|
-21.9
|
-20.8
|
-15.2
|
-14.36
|
-11.31
|
Net income
1 |
-7.6
|
-20.5
|
-14.1
|
-35.1
|
-42.3
|
-54.7
|
-116.1
|
-61.3
|
-31.2
|
-26
|
-18.79
|
-16.58
|
-12.11
|
-11.86
|
-8.808
|
Net margin
|
-4.73%
|
-12.43%
|
-7.86%
|
-22.44%
|
-23.79%
|
-30.19%
|
-63.27%
|
-31.94%
|
-15.87%
|
-12.86%
|
-9.15%
|
-7.96%
|
-5.56%
|
-5.53%
|
-3.97%
|
EPS
2 |
-0.1000
|
-0.2600
|
-0.1800
|
-0.4300
|
-0.5200
|
-0.6700
|
-1.420
|
-0.7500
|
-0.3600
|
-0.2900
|
-0.1767
|
-0.1567
|
-0.1200
|
-0.1350
|
-0.0950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/1/22
|
2/28/23
|
5/3/23
|
8/3/23
|
11/6/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
96.6
|
108
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
340
|
115
|
102
|
93.9
|
116
|
163
|
Leverage (Debt/EBITDA)
|
0.4427
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
75.1
|
-64.6
|
162
|
-152
|
-174
|
4
|
16
|
39
|
ROE (net income / shareholders' equity)
|
12.4%
|
-5.6%
|
0.15%
|
-12.1%
|
-2.71%
|
0.37%
|
2.98%
|
5.28%
|
ROA (Net income/ Total Assets)
|
9.27%
|
-3.57%
|
0.1%
|
-1.92%
|
-1.93%
|
0.24%
|
2.01%
|
3.58%
|
Assets
1 |
49.62
|
-
|
-26,667
|
5,830
|
13,662
|
-37,704
|
-2,948
|
-704.4
|
Book Value Per Share
2 |
14.80
|
11.70
|
12.10
|
10.90
|
8.710
|
8.430
|
8.450
|
8.690
|
Cash Flow per Share
2 |
1.100
|
-
|
0.2300
|
-1.320
|
-1.340
|
1.910
|
2.230
|
-
|
Capex
1 |
8.6
|
10.2
|
18
|
45.3
|
63.2
|
19
|
20
|
21
|
Capex / Sales
|
1.01%
|
1.83%
|
2.61%
|
6.68%
|
8.39%
|
2.29%
|
2.23%
|
2.19%
|
Announcement Date
|
8/13/19
|
2/23/21
|
2/24/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
25.47
USD Average target price
25.1
USD Spread / Average Target -1.45% Consensus |
1st Jan change
|
Capi.
|
---|
| +33.07% | 2.31B | | -1.29% | 12.64B | | -0.47% | 8.46B | | +22.61% | 5.27B | | -2.03% | 4.49B | | -53.56% | 3.11B | | +19.30% | 2.87B | | -8.42% | 2.23B | | -3.55% | 1.89B | | +5.37% | 1.64B |
Diagnostic & Testing Substances
|